lotrevaGHK and GHK-Cu need separate records.
GHK refers to the tripeptide glycyl-histidyl-lysine; GHK-Cu denotes its copper complex. A paper that compares the peptide, its copper complex and free copper is asking a more specific question than whether “copper peptides work.” Preserve the exact material and comparator names when summarizing it.
Sources: 2015 primary study: GHK, GHK-Cu and TGF-beta secretion in dermal fibroblasts
What selected primary studies examined.
A 1992 study measured sulfated glycosaminoglycan synthesis in cultured human fibroblasts. The word “human” identifies the origin of the cells; it does not turn a culture experiment into a clinical trial. A 2015 study examined TGF-beta secretion with GHK, GHK-Cu and copper controls in dermal fibroblasts. These are cellular endpoints.
| Study | Measured question | Appropriate scope |
|---|---|---|
| 1992 fibroblast study | Glycosaminoglycan synthesis | A cellular biochemical response |
| 2015 fibroblast study | TGF-beta secretion with different materials and controls | A context-dependent signaling measurement |
| 2007 fibroblast study | Collagen-related measurements with LED exposure and copper peptide | An experiment involving combined interventions |
Sources: 1992 primary study: GHK-Cu and glycosaminoglycan synthesis in cultured fibroblasts; 2015 primary study: GHK, GHK-Cu and TGF-beta secretion in dermal fibroblasts
Read combined interventions carefully.
The 2007 paper investigated fibroblast cultures exposed to LED irradiation and copper peptide conditions. When an experiment combines interventions, attributing every result to the peptide alone skips a necessary comparison. Read the individual control groups and the measurement method before assigning an explanation.
Sources: Huang et al. (2007): copper peptide and LED exposure in fibroblast cultures
Keep the translation gap visible.
For each paper, complete a sentence in this form: “In this model, under these conditions, the investigators measured this endpoint.” Then write the additional evidence needed for a broader claim. A statement about visible skin changes, tissue repair in patients or long-term systemic safety requires evidence addressing that outcome directly.
FDA’s GHK-Cu safety entry specifically concerns injectable routes, citing limited human safety data and potential immunogenicity associated with aggregation and impurities. Do not silently extend either laboratory findings or that route-specific regulatory entry to every different formulation and use.
Sources: FDA: bulk substances with potential significant safety risks
Questions for a research summary.
Record the exact complex, the cell type, the control material, the endpoint and whether another intervention was present. Note whether the cited document was an abstract or full paper. Keep the authors’ observed result separate from your proposed explanation for it.
Lotreva has not tested or verified the material used in these publications. This article offers a reading framework, not a claim that a Lotreva vial reproduces a published experiment or is suitable for human use.